Drug Name:
DILATRATE-SR Rx
Generic Name and Formulations:
Isosorbide dinitrate 40mg; sust-rel caps.
Company:
Endo Pharmaceuticals
Therapeutic Use:
Indications for DILATRATE-SR:
Prophylaxis and treatment of angina. Not for acute attacks.
Adult:
See full labeling. Allow at least an 18-hour interval daily between doses to avoid development of tolerance. Max 160mg/day.
Children:
Not established.
Contraindications:
Concomitant PDE inhibitors (eg, sildenafil, tadalafil, vardenafil, avanafil) or riociguat.
Warnings/Precautions:
Recent MI. CHF. Volume depletion. Hypotension. Hypertrophic cardiomyopathy. Monitor standing blood pressure when increasing doses. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
Pharmacological Class:
Nitrate.
Interactions:
See Contraindications. Hypotension potentiated with alcohol, other vasodilators.
Adverse Reactions:
Headache, transient lightheadedness, orthostatic hypotension; rare: syncope, angina, rebound hypertension.
How Supplied:
Caps—100
Sign Up for Free e-newsletters
ONA Articles
- Takeda to Collaborate With MSKCC on CAR-T Therapies for Multiple Myeloma
- Shorter Duration of Cryotherapy as Effective as Standard Therapy Prior to HSCT for Multiple Myeloma
- Sequential Immunotherapy, Targeted Therapy Linked to Cutaneous Adverse Events in Advanced Melanoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- 9/11 Responders May Have Higher Head and Neck Cancer Risk
- Oncology Nurse Navigation Facilitates Timely Treatment of Pancreatic Cancer
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Oncology Nurses Weigh In on Their Patient-Centered Communication Practices, Needs
- Substitute for Lidocaine
- CART cell therapy for prostate cancer: status and promise
- Immunotherapy for HER2-positive Breast Cancer: Recent Advances and Combination Therapeutic Approaches
- Survey Demonstrates Relationship Between Symptom Burden, Medical Disability Leave Among Myeloproliferative Neoplasms
- A Review of Clinical Outcomes in Patients With Early-Stage Burkitt Lymphoma
- FDA: Number of U.S. Women With Breast Implant-Caused Cancer Has Increased
- USPSTF Still Recommends Against Pancreatic Cancer Screening
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |